IRB #

IRB00011804

Title

A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors

Principal Investigator

Matthew Taylor

Study Purpose

For Phase 1b: To determine and confirm the maximum tolerated dose for lenvatinib in combination with 200mg of pembrolizumab

For Phase 2: To determine whether the combination of lenvatinib and pembrolizumab causes the size of the tumor to shrink

Medical Condition(s)

Non small cell lung cancer
Renal cell carcinoma
Endometrial cancer
Urothelial cancer
Squamous cell carcinoma of the head and neck
Melanoma

Eligibility Criteria

1. Male or female age 18 or older
2. Confirmed diagnosis of metastatic cancer of the above mentioned tumor types
3. Adequately controlled blood pressure with or without blood pressure medications
4. Other criteria apply

Age Range

18 - 100

Healthy Volunteers Needed

No

Duration of Participation

Treatment can continue until subjects experience disease progression or develop intolerable side effects. After treatment discontinuation, subjects will be contacted by phone about every three months.

Minors Included

No

Contact

Knight Clinical Trials Information Line
503-494-1080

Sponsor

Eisai, Inc

Recruitment End

12/31/2017

Compensation Provided

No


Go Back